FOXA2-initiated transcriptional activation of INHBA induced by methylmalonic acid promotes pancreatic neuroendocrine neoplasm progression
© 2024. The Author(s)..
Pancreatic neuroendocrine neoplasms (PanNENs) are a group of highly heterogeneous neoplasms originating from the endocrine islet cells of the pancreas with characteristic neuroendocrine differentiation, more than 60% of which represent metastases when diagnosis, causing major tumor-related death. Metabolic alterations have been recognized as one of the hallmarks of tumor metastasis, providing attractive therapeutic targets. However, little is known about the molecular mechanism of metabolic changes regulating PanNEN progression. In this study, we first identified methylmalonic acid (MMA) as an oncometabolite for PanNEN progression, based on serum metabolomics of metastatic PanNEN compared with non-metastatic PanNEN patients. One of the key findings was the potentially novel mechanism of epithelial-mesenchymal transition (EMT) triggered by MMA. Inhibin βA (INHBA) was characterized as a key regulator of MMA-induced PanNEN progression according to transcriptomic analysis, which has been validated in vitro and in vivo. Mechanistically, INHBA was activated by FOXA2, a neuroendocrine (NE) specific transcription factor, which was initiated during MMA-induced progression. In addition, MMA-induced INHBA upregulation activated downstream MITF to regulate EMT-related genes in PanNEN cells. Collectively, these data suggest that activation of INHBA via FOXA2 promotes MITF-mediated EMT during MMA inducing PanNEN progression, which puts forward a novel therapeutic target for PanNENs.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:81 |
|---|---|
| Enthalten in: |
Cellular and molecular life sciences : CMLS - 81(2024), 1 vom: 22. Jan., Seite 50 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Hu, Chunhua [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 16.02.2024 Date Revised 16.02.2024 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1007/s00018-023-05084-0 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM36742648X |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM36742648X | ||
| 003 | DE-627 | ||
| 005 | 20240217232318.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240122s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s00018-023-05084-0 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1297.xml |
| 035 | |a (DE-627)NLM36742648X | ||
| 035 | |a (NLM)38252148 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Hu, Chunhua |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a FOXA2-initiated transcriptional activation of INHBA induced by methylmalonic acid promotes pancreatic neuroendocrine neoplasm progression |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 16.02.2024 | ||
| 500 | |a Date Revised 16.02.2024 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2024. The Author(s). | ||
| 520 | |a Pancreatic neuroendocrine neoplasms (PanNENs) are a group of highly heterogeneous neoplasms originating from the endocrine islet cells of the pancreas with characteristic neuroendocrine differentiation, more than 60% of which represent metastases when diagnosis, causing major tumor-related death. Metabolic alterations have been recognized as one of the hallmarks of tumor metastasis, providing attractive therapeutic targets. However, little is known about the molecular mechanism of metabolic changes regulating PanNEN progression. In this study, we first identified methylmalonic acid (MMA) as an oncometabolite for PanNEN progression, based on serum metabolomics of metastatic PanNEN compared with non-metastatic PanNEN patients. One of the key findings was the potentially novel mechanism of epithelial-mesenchymal transition (EMT) triggered by MMA. Inhibin βA (INHBA) was characterized as a key regulator of MMA-induced PanNEN progression according to transcriptomic analysis, which has been validated in vitro and in vivo. Mechanistically, INHBA was activated by FOXA2, a neuroendocrine (NE) specific transcription factor, which was initiated during MMA-induced progression. In addition, MMA-induced INHBA upregulation activated downstream MITF to regulate EMT-related genes in PanNEN cells. Collectively, these data suggest that activation of INHBA via FOXA2 promotes MITF-mediated EMT during MMA inducing PanNEN progression, which puts forward a novel therapeutic target for PanNENs | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Epithelial–mesenchymal transition | |
| 650 | 4 | |a FOXA2 | |
| 650 | 4 | |a INHBA | |
| 650 | 4 | |a Metabolic alterations | |
| 650 | 4 | |a Pancreatic neuroendocrine neoplasm | |
| 650 | 4 | |a Tumor progression | |
| 650 | 7 | |a FOXA2 protein, human |2 NLM | |
| 650 | 7 | |a Hepatocyte Nuclear Factor 3-beta |2 NLM | |
| 650 | 7 | |a 135845-92-0 |2 NLM | |
| 650 | 7 | |a inhibin beta A subunit |2 NLM | |
| 650 | 7 | |a Inhibin-beta Subunits |2 NLM | |
| 650 | 7 | |a 93443-12-0 |2 NLM | |
| 650 | 7 | |a Methylmalonic Acid |2 NLM | |
| 650 | 7 | |a 8LL8S712J7 |2 NLM | |
| 700 | 1 | |a Ye, Mujie |e verfasserin |4 aut | |
| 700 | 1 | |a Bai, Jianan |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Pengfei |e verfasserin |4 aut | |
| 700 | 1 | |a Lu, Feiyu |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Jinhao |e verfasserin |4 aut | |
| 700 | 1 | |a Xu, Yanling |e verfasserin |4 aut | |
| 700 | 1 | |a Yan, Lijun |e verfasserin |4 aut | |
| 700 | 1 | |a Yu, Ping |e verfasserin |4 aut | |
| 700 | 1 | |a Xiao, Zequan |e verfasserin |4 aut | |
| 700 | 1 | |a Gu, Danyang |e verfasserin |4 aut | |
| 700 | 1 | |a Xu, Lin |e verfasserin |4 aut | |
| 700 | 1 | |a Tian, Ye |e verfasserin |4 aut | |
| 700 | 1 | |a Tang, Qiyun |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cellular and molecular life sciences : CMLS |d 1997 |g 81(2024), 1 vom: 22. Jan., Seite 50 |w (DE-627)NLM090610393 |x 1420-9071 |7 nnns |
| 773 | 1 | 8 | |g volume:81 |g year:2024 |g number:1 |g day:22 |g month:01 |g pages:50 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s00018-023-05084-0 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 81 |j 2024 |e 1 |b 22 |c 01 |h 50 | ||